Allmed released its performance forecast for 2024, expecting a net profit of RMB 305 million to RMB 355 million, an increase of 176.27% to 221.56% compared to the same period last year. In recent years, the company has adhered to long-termism, deployed multiple advanced production capacities, implemented various technological upgrades, and laid out new markets and channels. In 2024, the company achieved an increase in market share for traditional products, boosted sales of functional dressings and other products, and realized revenue growth. At the same time, in 2023, the company made corresponding impairment provisions for assets showing signs of impairment, with a total provision for credit and asset impairment losses amounting to RMB 102.56 million, resulting in a lower performance base for 2023
